Skip to content

Celcuity CELC Cash and cash equivalents, end of period

Cash and cash equivalents, end of period at other companies

Eli Lilly logo
Eli LillyLLY
BridgeBio Pharma logo
BridgeBio PharmaBBIO
Tango Therapeutics logo
Tango TherapeuticsTNGX

Other financials

Income statement

See full
Operating income-$50.5M-39.8%
Net income-$52.8M-42.8%
EPS (diluted)-$0.97-12.8%

Balance sheet

See full
Cash & equivalents$145.2M+781%
Total debt$137.9M+30.7%
Total equity$53.5M-38.2%
Total assets$410.2M+88.0%

Cash flow

See full
Operating cash flow-$55.1M-53.6%
CapEx$249.0K+315%
Free cash flow-$55.3M-54.0%

Valuation

See full
Market cap$4.4B+1,370%

Returns & leverage

See full
Return on equity-275.2%-990pp
Debt / equity2.6×+1.4×
Current ratio12.3×+5.7×

Where this comes from

Reported directly by Celcuity in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations.

The official record: Celcuity’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Celcuity's cash and cash equivalents, end of period.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Celcuity's cash and cash equivalents, end of period?
Celcuity (CELC) reported cash and cash equivalents, end of period of $145.19M in Q1 2026.
How has Celcuity's cash and cash equivalents, end of period changed year-over-year?
Celcuity's cash and cash equivalents, end of period increased by 781.1% year-over-year, from $16.48M to $145.19M.
What is the long-term trend for Celcuity's cash and cash equivalents, end of period?
Over 5 years (2020 to 2025), Celcuity's cash and cash equivalents, end of period has grown at a 70.1% compound annual growth rate (CAGR), from $11.64M to $165.7M.